Leptin in Type 2 Diabetic or Myotonic Dystrophic Women

Background:

Insulin resistance is an important determinant of circulating leptin concentrations in humans, but its independent contribution on plasma leptin levels are controversial. In the present study, we characterized plasma leptin levels and their regulation in women with 2 different insulin resistance states: type 2 diabetes and myotonic dystrophy disease, and in controls.

Material and Methods:

We studied 3 groups of women: 21 type 2 diabetic patients, 20 myotonic dystrophic patients and a control group of 20 normoglycemic subjects, matched in age and body mass index. Body composition, fasting glucose and insulin, IGF-I, IGF-binding protein-3 and leptin were studied. Body composition was measured using a bioelectrical impedance analyser. Insulin sensitivity (in percentage) was modeled according to a computer-based homeostasis model assessment model. Data are expressed in mean ± SEM.

Results:

In both groups of patients, glucose concentrations were higher in type 2 diabetic patients than in myotonic dystrophic patients, and insulin concentrations and insulin sensitivity were similar in the 2 groups of patients (82.4 ± 18.6 % in type 2 diabetic patients vs. 69.7 ± 9.7 % in myotonic dystrophic patients, p = 0.2) and lower than in controls. Serum leptin and leptin/fat mass ratio were higher in myotonic dystrophic patients than in type 2 diabetic patients (30 ± 4.9 ng/ml vs. 17.7 ± 2.6 ng/ml, p = 0.03 and 2.32 ± 0.69 ng/ml/kg vs. 1.07 ± 0.2 ng/ml/kg, p = 0.02, respectively) or those found in controls. In type 2 diabetic patients, leptin concentrations were correlated with body mass index and body fat, and in myotonic dystrophic patients leptin concentrations were correlated with age, body mass index, fasting insulin and lower insulin sensitivity, whereas leptin concentrations were not correlated with body fat.

Conclusions:

These findings suggest that leptin concentrations and regulation in myotonic dystrophic patients are different from type 2 diabetes.

Body Composition - Body Fat - Fat Mass - Insulin - Insulin Resistance - Leptin - Myotonic Dystrophy - Type 2 Diabetes

References:

• 1 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse ob gene and its human homologue.  Nature. 1994;  372 425-432
• 2 Considine R, Sinha M K, Heiman M, et al. Serum immunoreactive leptin concentrations in normal weight and obese humans.  N Engl J Med. 1996;  334 292-295
• 3 Segal K R, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men.  Diabetes. 1996;  45 988-991
• 4 Widjaja A, Stratton I M, Horn R, Holman R R, Turner R, Brabant G. UKPDS 20: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects.  J Clin Endocrinol Metab. 1997;  82 654-657
• 5 Haffner S M, Stern M P, Miettinem H, Wei M, Gingerich R L. Leptin concentrations in diabetic and nondiabetic Mexican-Americans.  Diabetes. 1996;  45 822-824
• 6 Dua A, Hennes M I, Hoffmann R G, et al. Leptin: a significant indicator of total body fat but not visceral fat and insulin insensitivity in African-American women.  Diabetes. 1996;  45 1635-1637
• 7 Malmström R, Taskinen M -R, Karonen S -L, Yki-Järvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM.  Diabetologia. 1996;  39 993-996
• 8 Gómez J M, Molina A, Fernández-Castañer M, Casamitjana R, Martínez-Matos J A, Soler J. Insulin regulation of leptin synthesis and secretion in humans: the model of myotonic dystrophy.  Clin Endocrinol (Oxf). 1999;  50 569-575
• 9 Fernández-Real J M, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance.  Diabetes. 1998;  47 1757-1762
• 10 Fernández-Real J M, Molina A, Broch M, et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy.  Diabetes. 1999;  48 1108-1112
• 11 Lukaski H C, Bolonchuk W W, Hall C B, Siders W A. Validation of tetrapolar bioelectrical impedance method to assess human body composition.  J Applied Physiol. 1986;  69 1327-1332
• 12 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 13 Fernández-Castañer M, Biarnés J, Camps I, Ripollés J, Gómez N, Soler J. Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus.  Diab Med. 1996;  13 953-959
• 14 Shimuzu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.  Diabetes Care. 1998;  21 1470-1474
• 15 Livingston J N, Moxley III R T. Myotonic dystrophy. Phenotype-genotype and insulin resistance.  Diab Rev. 1994;  2 29-42
• 16 Hillier T A, Fryburg D A, Jahn L A, Barret E J. Extreme hyperinsulinemia unmasks insulin’s effect to stimulate protein synthesis in the human forearm.  Am J Physiol. 1998;  274 (Endocrinol Metab 37) E1067-1074
• 17 Moxley R T, Griggs R C, Forbes G B, Goldblatt D, Donohoe K. Influence of muscle wasting on oral glucose tolerance testing.  Clin Sci. 1983;  64 601-609
• 18 Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
• 19 Seck T, Englaro P, Blum W F, et al. Leptin concentrations in serum from a randomly recruited sample of 50 to 80-year-old men and women:positive association with plasma insulin-like growth factors (IFGs) and IGF-binding protein-3 in lean, but not in obese, individuals.  Eur J Endocrinol. 1998;  138 70-75
• 20 Taylor S I, Barr V, Reitman M. Does leptin contribute to diabetes caused by obesity?.  Science. 1996;  274 1151-1152
• 21 Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin.  Science. 1996;  274 1185-1188